Control Bionics Reports Commercial Momentum
Key points
- First NextLevel tablets shipped, marking initial revenue
- NeuroStrip commercial footprint expands to 20 organizations across four countries
- Germany distribution partner expected within weeks
Full summary
Control Bionics Limited (ASX: CBL) announced significant commercial progress across its Assistive Technology and NeuroTechnology Solutions strategic pillars. The first NextLevel tablets have shipped, marking initial revenue from what the Company expects to be an important growth driver in FY27. NeuroStrip, the Company's wearable surface electromyography (sEMG) platform, has signed agreements with 20 organizations across Australia, New Zealand, the United States, and the United Kingdom. Additionally, the Company expects to announce its first German distribution partner in the coming weeks, with rollout and onboarding already scheduled for later in August.
Guidance
NextLevel tablets revenue expected to be a meaningful contributor to FY27
Outlook
The Company enters the first quarter of FY27 with a clear set of near-term execution milestones across both pillars.
Summary generated by a large language model. Please interpret with care.